BlueRock Therapeutics
Business Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
238 Main St Ste 3, Cambridge, Massachuse...Phone Number
(857) 299-7589Website
www.bluerocktx.comRevenue
$42.3 MillionIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
4
3
1
5
1
2
About BlueRock Therapeutics
BlueRock Therapeutics, a wholly owned and independently operated subsidiary of Bayer AG, is a leading engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock Therapeutics' cell+gene platform harnesses the power of cells for new medicines across neurology, cardiology and immunology indications. BlueRock Therapeutics' cell differentiation technology recapitulates the cell's developmental biology to produce authentic cell therapies, which are further engineered for additional function. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function. BlueRock's culture is defined by scientific innovation, highest ethical standards and an urgency to bring transformative treatments to all who would benefit.Explore more
BlueRock Therapeutics Org Chart
PJ
Senior VP, Technical Development Strategy
MJ
Senior VP, Quality Assurance
JG
Vice President, Engineering & Msat
YW
Vice President, Head of Biometrics
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BlueRock Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if BlueRock Therapeutics had a recent Job posting/layoffs
BlueRock Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if BlueRock Therapeutics is spiking on competitors!
Product Launch: Get notified when BlueRock Therapeutics launches new products
Check if BlueRock Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once BlueRock Therapeutics has new funding data
Earning: See what the market has to say on BlueRock Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at BlueRock Therapeutics
Recommended Actions
Find VP level buyers at BlueRock Therapeutics
Find more new buyers
Compare Similar Companies to BlueRock Therapeutics
Compare insights from companies similar to BlueRock Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
BlueRock Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
BlueRock Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about BlueRock Therapeutics.
BlueRock Therapeutics Tech Stack
A closer look at the technologies used by BlueRock Therapeutics
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Open Position
Open Position
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
BlueRock Therapeutics News & Media
BlueRock Therapeutics announces first patient receives investigational therapy in Phase 1/2a clinical trial of OpCT-001 for the treatment of primary photoreceptor diseases
BERLIN & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bayer AG and BlueRock Therapeutics LP, a clinical-stage cell therapy company and wholly owned subsidiary of Bayer AG, today announced that the first patient received the investigational therapy in CLARICO, a Phase 1/2a clinical trial of OpCT-001, an investigational induced pluripotent stem cell (iPSC)-derived cell therapy for the treatment of primary photoreceptor diseases. OpCT-001 is the first iPSC-derived investigational cell therapy to be clinicalBlueRock Therapeutics announces publication in Nature of 18-month data from Phase 1 clinical trial for bemdaneprocel, an investigational cell therapy for Parkinson’s disease
•Treatment with bemdaneprocel did not cause any serious adverse events related to cell therapy following discontinuation of immunosuppression after one year in the trial’s high and low dose cohorts. •Bemdaneprocel is the first investigational allogeneic pluripotent stem cell-derived cell therapy for Parkinson’s disease and the most clinically advanced cell therapy being investigated for treating the disease. •BlueRock expects to initiate a Phase 3 clinical trial for bemdaneprocel in H1 2025. •TrBlueRock Therapeutics’ Investigational Cell Therapy Bemdaneprocel for Parkinson’s Disease Shows Positive Data at 24-Months
BERLIN & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bayer AG and BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG today announced positive 24-month data from exPDite, a Phase 1 clinical trial of bemdaneprocel, an investigational cell therapy for the treatment of Parkinson's disease. Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s disease. TheBlueRock Therapeutics announces FDA clearance of IND application for investigational iPSC-derived cell therapy OpCT-001 for the treatment of primary photoreceptor diseases
* OpCT-001 is the first iPSC-derived investigational cell therapy to be clinically tested for treating primary photoreceptor diseases * Primary photoreceptor diseases are a subgroup of inherited retinal disorders that affect the structure and function of the photoreceptor cells in the retina, leading to irreversible vision loss in children and adults * BlueRock plans to conduct a Phase 1/2a clinical study in the U.S. * OpCT-001 is the first iPSC-derived investigational cell therapy to be
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BlueRock Therapeutics
Sign Up For FreeTo access detailed company insights
BlueRock Therapeutics, a wholly owned and independently operated subsidiary of Bayer AG, is a leading engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock Therapeutics' cell+gene platform harnesses the power of cells for new medicines across neurology, cardiology and immunology indicati... Read More
